Search results

1. BeOne tries to repeat the inhibitor-degrader double

   … BG-68501 showed 6% uORR in 37 solid tumour patients at ASCO 2025 BG-75202 KAT6A/B inhibitor Starting …

   
    

   Jacob Plieth
    
   - 05/19/2026 - 19:49

2. Exelixis claims a next-generation colorectal win

   … Monotx & combos Safety, ORR, PFS, OS Data at ASCO 2025 in 1st-line renal: ORR 63% with zanza + Opdivo …

   
    

   Madeleine Armstrong
    
   - 05/19/2026 - 19:49

3. DLL3 goes trispecific

   … Zelgen China ph2 data in 3rd-line SCLC presented at ASCO 2025: ORR 63% & 58% with 10mg Q2W & 30mg Q2W …

   
    

   Madeleine Armstrong
    
   - 05/19/2026 - 19:49

4. Lyell takes on J&J and Gilead

   … in r/r BCL Venue ICML 2025 EHA 2025* ASCO 2025** Setting 3rd-line-plus 2nd-line … RP2D of 2m Car-T cells. Source: company releases, EHA & ASCO 2025.   Data also looked good in the second …

   
    

   Madeleine Armstrong
    
   - 05/19/2026 - 19:49

5. NextCure joins Merck in an ovarian target

   … CUSP06 OnCusp Therapeutics ADC Ph1 US data at ASCO 2025: cORR 20% (5/25) in PROC HS-20124 …

   
    

   Madeleine Armstrong
    
   - 05/19/2026 - 19:49

6. More front-line Imdelltra details emerge

   … OS Confirmatory trial following AA May 2024; data at ASCO 2025: 40% reduction in risk of death with Imdelltra vs …

   
    

   Madeleine Armstrong
    
   - 05/19/2026 - 19:49

7. Merck speeds its KRAS into the colorectal front line

   … + chemo combo) to begin Jul 2025 Ph1 Kandlelit-001 at ASCO 2025: ORR 58% (7/12) in 1st-line pts receiving triplet …

   
    

   Madeleine Armstrong
    
   - 05/19/2026 - 19:49

8. AbbVie's telisotuzumab conjugate take two

   … . This was known to enrol cMet overexpressers, but an ASCO 2025 trials-in-progress poster revealed the precise …

   
    

   Jacob Plieth
    
   - 05/19/2026 - 19:49

9. ASCO 2025 movers – bispecifics to the rescue

   ASCO 2025 movers – bispecifics to the rescue … presented at this year's conference.   Winners of ASCO 2025 Company Share price change … use for these bispecific MAbs.   Losers of ASCO 2025 Company Share price change …

   
    

   Jacob Plieth
    
   - 05/19/2026 - 19:49

10. ASCO 2025 – J&J challenges its own multiple myeloma T-cell engagers

    ASCO 2025 – J&J challenges its own multiple myeloma T-cell … Note: RP2D=recommended phase 2 dose. Source: ASCO 2025. This story has been updated. …

    
     

    Madeleine Armstrong
     
    - 05/19/2026 - 19:49